Published in Surgery Litigation and Law Weekly, July 24th, 2009
"Betrixaban represents an important addition to our late-stage portfolio with the potential to be a significant medicine in the Factor Xa inhibitor class," said Luciano Rossetti M.D., senior vice president and franchise head, Atherosclerosis and Cardiovascular, Merck Research Laboratories. "This agreement...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Surgery Litigation and Law Weekly